Roxadustat before major surgery proves feasible and tolerable but efficacy remains unproven
A 150-patient phase 2a trial found preoperative roxadustat safe to give before major surgery, with no excess complications. Whether it protects organs is still unknown.
Summary
Roxadustat is a drug that switches on the body's low-oxygen response by blocking prolyl hydroxylase enzymes. In animal work it has reduced injury when blood flow returns to oxygen-starved tissue, sped wound healing, and improved survival in sepsis. Researchers in Perth tested whether giving it before major surgery is workable. In this pilot trial, 148 adults (median age 65) received either roxadustat 100 mg or placebo for three alternate-day doses, the last on the morning of surgery. Preoperative adverse events were nearly identical (28% vs 27%), and no serious adverse reactions occurred. Postoperative complications within 30 days were also similar (31% vs 30%), as were days alive out of hospital. The trial was too small to show benefit or rule out harm. It shows the approach is feasible, with high drug compliance, and sets the stage for larger studies of organ protection.
Detailed Summary
Surgery is a major stress for older bodies, and postoperative complications remain a leading cause of death. Drugs that prime tissues to withstand low oxygen and inflammation before an operation could, in theory, protect organs. That makes this a question of resilience, which matters as people age and face more surgery.
Roxadustat is a first-in-class prolyl hydroxylase inhibitor. By blocking these oxygen-sensing enzymes, it stabilizes hypoxia-inducible factors, the cell's master low-oxygen response. In experimental models, this has reduced ischemia-reperfusion injury, accelerated wound healing, and improved survival in sepsis. Those are animal and laboratory signals, and this trial was designed to test tolerability, not to prove them in people.
The researchers ran a phase 2a, single-center, double-blind, randomized pilot trial in Perth. A total of 150 patients having major elective noncardiac surgery were assigned to roxadustat 100 mg or placebo, given as three alternate-day doses ending on the morning of surgery. Co-primary outcomes were preoperative adverse events and standardized postoperative complications within 30 days.
Among 148 patients who received at least one dose (median age 65, 35% female), preoperative adverse events occurred in 28% on roxadustat and 27% on placebo (odds ratio 1.03; 95% CI 0.50-2.12). No serious adverse reactions occurred. Among 143 who had surgery, complications occurred in 31% versus 30% (odds ratio 1.03; 95% CI 0.51-2.10). Days alive out of hospital were similar. Enrollment was about 90 patients per year with high compliance.
The result supports feasibility and shows no obvious safety signal at this scale. It does not show protection, and the authors state that uncertainty remains about both safety and efficacy. The confidence intervals are wide, so modest harm or benefit cannot be excluded. Mechanism, function and outcome effects were not demonstrated here; this is a feasibility step toward a larger efficacy trial.
Key Findings
- Preoperative adverse events were similar: 28% with roxadustat versus 27% with placebo (OR 1.03, 95% CI 0.50-2.12).
- No serious adverse reactions occurred in the 148 patients who received at least one dose.
- 30-day postoperative complications were 31% versus 30% (OR 1.03, 95% CI 0.51-2.10); no organ protection was shown.
- Days alive out of hospital within 30 days were similar between groups.
- Enrollment (about 90 per year) and drug compliance were high, supporting a larger trial.
Methodology
Phase 2a, single-center, double-blind, placebo-controlled randomized pilot trial of 150 adults having major elective noncardiac surgery. Roxadustat 100 mg or placebo was given for three alternate-day doses, the last on the operative morning. Co-primary outcomes were preoperative adverse events and standardized postoperative complications within 30 days.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The pilot was small and single-center, so the wide confidence intervals cannot exclude meaningful benefit or harm, and it was not powered for efficacy. One author reports consulting ties to prolyl hydroxylase inhibitor developers, and the abstract gives no data on organ-injury biomarkers or the hypoxia-response mechanism.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
